Project Details
Description
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment
| Status | Active |
|---|---|
| Effective start/end date | 2/6/25 → 10/17/35 |
Funding
- JANSSEN RESEARCH & DEVELOPMENT, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.